Skip to main content

This job has expired

You will need to login before you can apply for a job.

Scientist II/Senior Scientist I - Nucleic Acid Detection

Employer
Mammoth Biosciences
Location
Brisbane, CA
Start date
Oct 6, 2024
View more categoriesView less categories
Discipline
Science/R&D, Biotechnology
Required Education
Masters Degree/MBA
Position Type
Full time
Hotbed
Biotech Bay

Job Details

OPPORTUNITY
Mammoth’s Assay Development team is hiring a Scientist II/Sr. Scientist I to develop nucleic acid testing assays to support the development of novel CRISPR-based therapeutics. The successful candidate will develop, optimize, and routinely execute DNA and RNA quantification assays and contribute to de novo assay development. This position requires a strong background in plate based assays, excellent problem-solving skills, analytical thinking, and the ability to work collaboratively in a fast-paced environment.

KEY RESPONSIBILITIES
  • Contribute creatively to the design and development of novel assays for characterizing therapeutic nucleic acids for CRISPR-based therapies
  • Develop scalable and rigorous assays for measuring gene expression, RNA stability and degradation, pharmacokinetics, and therapeutic efficacy
  • Liaise with CROs to qualify and validate assays developed by the team
  • Routinely develop standardized protocols for assays
  • Plan, design, execute and designate assays for CRISPR therapeutic development
  • Provide consultation to other program teams on dPCR, ddPCR, qPCR, RNA-seq and other relevant assays routinely used in early research and later stage drug development
  • Train and provide instructions to junior members of assay development and associated teams on assays
  • Document experiments in electronic lab notebooks and present present data when needed
  • Provide support to automation team scientists to onboard protein detection protocols to high throughput systems
  • Lead team and routinely develop and improve processes to better team functionality

REQUIRED QUALIFICATIONS
  • PhD in Molecular Biology, Cell Biology, Biochemistry, Bioengineering, or related fields with 3+ years of relevant professional experience in industry or academia following completion of PhD. For non-PhD candidates, an MS degree with 6+ years of professional experience is required. 
  • At least 3 years of hands-on experience with digital PCR, qRT-PCR, droplet digital PCR, RNA-seq and other nucleic acid based molecular biology techniques
  • 2+ years of hands-on experience in at least two of the following areas as they relate to gene therapy drug development: NAT assay validation and qualification; Design and implementation and novel DNA and RNA quantification methods; Generating robust standardized protocols and SOPs as release assays
  • Prior experience with CRO management
  • Prior experience filing INDs for gene therapies

PREFERRED QUALIFICATIONS
  • Background in transcriptome analyses, RNA-seq, single cell RNA-seq
  • Background knowledge of CRISPR-based gene editing therapies and modalities including insertions, base and prime editing, and epigenetic editing
  • 1+ years of experience managing direct reports
  • Working proficiency with common software and data analysis tools (Benchling, Excel, GraphPad Prism, JMP, Biorender)
  • Strong verbal and written communication skills
  • Active engagement with concepts of diversity and inclusion 

BENEFITS
  • Company-paid health/vision/dental benefits
  • Unlimited vacation and generous sick time
  • Company-sponsored meals and snacks
  • Wellness, caregiver and ergonomics benefits
  • 401(k) with company matching

Base Salary Range: $135,000 - $155,000

Actual base salary will be determined by relevant professional experience, applicable skills, and internal equity.

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.

Mammoth Biosciences requires that all employees be vaccinated against COVID as a condition of at-will employment, with exceptions for medical or religious reasons in compliance with local, state, and federal law. 

Company

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

Facebook  Twitter  Instagram

Company info
Website
Phone
(650) 294-8583
Location
South San Francisco
CA
94080
US

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert